Biologics  	Biologics  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
and  	and  	 CC	O
ankylosing  	ankylosing  	 NNS	B-NP
spondylitis  	spondylitis  	 VBP	O
There  	There  	 EX	O
are  	are  	 VBP	O
clear  	clear  	 JJ	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
picture  	picture  	 NN	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
between  	between  	 IN	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
( 	( 	 -LRB-	O
RA 	RA 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
ankylosing  	ankylosing  	 JJ	B-NP
spondylitis  	spondylitis  	 NNS	I-NP
( 	( 	 -LRB-	O
AS 	AS 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Biologic  	Biologic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
targeting  	targeting  	 VBG	I-NP
TNF-alpha  	TNF-alpha  	 NNS	I-NP
are  	are  	 VBP	O
efficacious  	efficacious  	 VBN	O
in  	in  	 IN	O
both  	both  	 DT	O
diseases 	diseases 	 NNS	O
,  	,  	 ,	O
with  	with  	 IN	O
some  	some  	 DT	O
tendency  	tendency  	 NN	O
to  	to  	 TO	O
work  	work  	 VB	O
even  	even  	 RB	O
better  	better  	 JJR	O
in  	in  	 IN	O
spondyloarthritides  	spondyloarthritides  	 NNS	B-NP
( 	( 	 -LRB-	O
SpA 	SpA 	 NNP	B-NP
)  	)  	 -RRB-	O
on  	on  	 IN	O
a  	a  	 DT	O
clinical  	clinical  	 JJ	B-NP
basis 	basis 	 NN	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
anti-TNF  	anti-TNF  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
was  	was  	 VBD	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
inhibit  	inhibit  	 VB	O
radiographic  	radiographic  	 JJ	B-NP
progression  	progression  	 NN	I-NP
in  	in  	 IN	O
RA  	RA  	 NNP	B-NP
but  	but  	 CC	O
not  	not  	 RB	O
in  	in  	 IN	O
AS 	AS 	 NNP	O
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
probably  	probably  	 RB	O
due  	due  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
outstanding  	outstanding  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
pathogenesis 	pathogenesis 	 NNS	B-NP
:  	:  	 :	O
while  	while  	 IN	O
in  	in  	 IN	O
RA  	RA  	 NNP	B-NP
osteodestructive  	osteodestructive  	 VBD	O
lesions  	lesions  	 JJ	O
such  	such  	 JJ	O
as  	as  	 IN	O
erosions  	erosions  	 JJ	O
predominate 	predominate 	 NN	O
,  	,  	 ,	O
AS  	AS  	 NNP	O
patients  	patients  	 NNS	O
will  	will  	 MD	O
rather  	rather  	 RB	O
develop  	develop  	 VB	O
osteoproliferative  	osteoproliferative  	 JJ	B-NP
changes  	changes  	 NNS	I-NP
such  	such  	 JJ	O
as  	as  	 IN	O
syndesmophytes 	syndesmophytes 	 NN	B-NP
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
some  	some  	 DT	O
evidence  	evidence  	 NN	O
that  	that  	 IN	O
anti-TNF  	anti-TNF  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
may  	may  	 MD	O
show  	show  	 VB	O
longterm  	longterm  	 JJ	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
acceptable  	acceptable  	 JJ	O
safety  	safety  	 NN	O
profiles  	profiles  	 NNS	O
over  	over  	 IN	O
5-10  	5-10  	 JJ	O
years 	years 	 NNS	O
.  	.  	 .	O
There  	There  	 EX	O
are  	are  	 VBP	O
some  	some  	 DT	O
differences  	differences  	 NNS	O
between  	between  	 IN	O
the  	the  	 DT	O
agents.Whether  	agents.Whether  	 CD	O
the  	the  	 DT	O
recent  	recent  	 JJ	O
developments  	developments  	 NNS	B-NP
of  	of  	 IN	O
targeted  	targeted  	 JJ	O
therapies  	therapies  	 NNS	O
in  	in  	 IN	O
RA  	RA  	 NNP	B-NP
with  	with  	 IN	O
agents  	agents  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
rituximab 	rituximab 	 NN	B-NP
,  	,  	 ,	O
abatacept  	abatacept  	 NN	B-NP
and  	and  	 CC	O
tocilizumab  	tocilizumab  	 NNS	B-NP
will  	will  	 MD	O
also  	also  	 RB	O
work  	work  	 VB	O
for  	for  	 IN	O
AS  	AS  	 NNP	O
is  	is  	 VBZ	O
unknown  	unknown  	 VBN	B-NP
at  	at  	 IN	O
present 	present 	 JJ	O
.  	.  	 .	O
